Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9706129 | 0.86 | ALDH1A3 (0.39) | PGRADRA2AADRA2BHTR2AHRH1 | |
| SCHEMBL10372508 | 0.85 | KCNA5 (0.34) | KCNH2 | |
| SCHEMBL10429856 | 0.80 | ADRA2A (0.43) | PGRADRA2AADRA2BHTR2AHRH1 | |
| SCHEMBL3164644 | 0.79 | — | — | |
| SCHEMBL3163544 | 0.79 | BCHE (0.31) | PGRADRA2AADRA2BHTR2AHRH1 | |
| SCHEMBL3327499 | 0.78 | ALDH1A3 (0.34) | PGRADRA2AADRA2BHTR2AHRH1 | |
| Hydrochloric Acid SCHEMBL15412521 | 0.78 | ADRA2A (0.42) | PGRADRA2AADRA2BHTR2AHRH1 | |
| SCHEMBL5122376 | 0.78 | CYP1A2 (0.30) | — | |
| SCHEMBL1578641 | 0.78 | CYP1A2 (0.30) | — | |
| SCHEMBL4886698 | 0.77 | LDHA (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120329784-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC | 2012-12-27 | — | — | US | disclosed |
| EP-2523559-A1 | COMPOUNDS AND METHODS | GlaxoSmithKline LLC (US) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011088031-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088027-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC (US) | 2011-07-21 | — | — | WO | disclosed |
| EP-1630165-B1 | [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-2-YLUREA DERIVATIVE AND USE THEREOF | NIPPON KAYAKU KK (JP) | 2010-03-31 | — | — | EP | disclosed |
| US-7598244-B2 | [1,2,4]triazolo[1,5,a]pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1630165-A1 | [1,2,4 ]TRIAZOLO [1,5-A]PYRIMIDIN-2-YLUREA DERIVATIVE AND USE THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2006-03-01 | — | — | EP | disclosed |
| EP-1214318-B1 | IMIDAZO[1,2-A]PYRIDINE AND PYRAZOLO[2,3-A]PYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-10-08 | — | — | EP | disclosed |
| EP-0072932-B1 | PIPERAZINONES, THEIR PREPARATION AND USE | CASSELLA Aktiengesellschaft (DE) | 1990-01-17 | — | — | EP | disclosed |
| US-4659719-A | CALCIUM OR SEROTONIN ANTAGONIST | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1987-04-21 | — | — | US | disclosed |
| US-4598079-A | MEMORY DISORDERS | CASSELLA AKTIENGESELLSCHAFT (DE) | 1986-07-01 | — | — | US | disclosed |
| EP-0072932-A2 | Piperazinones, their preparation and use | CASSELLA Aktiengesellschaft (DE) | 1983-03-02 | — | — | EP | disclosed |
| US-4213994-A | Imidazolyl-(2)-carbinols having hypolipidemic action and process for preparing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | HLA-C, TPMT, TAP1 | PGR 3804/4885ADRA2A 2609/4885ADRA2B 2202/4885 |
| US-20120329784-A1 | COMPOUNDS AND METHODS | RB1, DHFR, NQO1 | PGR 111/4885ADRA2A 1175/4885ADRA2B 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.